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Abstract
Introduction Nonunion of femoral neck fractures frequently
occurs in elderly patients. In patients with rheumatoid arthritis,
reoperation rates after internal fixation of a displaced femoral
neck fracture increase by up to 60 %. Revision surgery
with arthroplasty is often preferred for nonunion of femoral
neck fractures because there are few effective options
for conservative treatment. Teriparatide (TPTD) is a human
parathyroid hormone analog and the only anabolic drug for
the treatment of severe osteoporosis.
Discussion There are two types of treatment regimens using
TPTD: a once-daily administration of recombinant type
TPTD and a once-weekly administration of a chemically
synthesized type. Although there have been some reports
showing that the once-daily recombinant type TPTD was
effective for nonunion treatment, the effect of a once-weekly
administration of the chemically synthesized type of TPTD
is unknown. This report shows the efficacy of the chemically
synthesized TPTD for the treatment of femoral neck fracture
nonunion in a patient with risk factors that include rheumatoid
arthritis and steroid intake.
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Introduction
Few options exist for the conservative treatment of delayed
union and nonunion fractures, including low-intensity
pulsed ultrasound (LIPUS), electrical stimulation, and
extracorporeal shock waves [1]. Two bone morphogenetic
proteins (BMPs), BMP-2 and BMP-7, are approved as drugs
for nonunion fractures, but their use may require additional
surgery and, until now, there have been no approved systemic
drugs for nonunion [2].
Intermittent administration of teriparatide (TPTD), a human
parathyroid hormone analog, is the only currently available
anabolic agent to stimulate osteoblast activity [3–6]. TPTD has
been shown to increase bone mass, improve bone quality, and
reduce the risk of fracture in patients with severe osteoporosis
[5, 6]. The daily or weekly administration of TPTD is
dependent on the type of TPTD utilized, with a recombinant
type used daily and a chemically synthesized type weekly
[7]. Several reports have demonstrated the efficacy of the
daily administration of recombinant TPTD in the treatment
of nonunion fractures [8–11]; however, it is still unknown
whether a weekly administration of chemically synthesized
TPTD could offer an effective alternative to the daily regimen.
The anabolic effect of the weekly dose of the chemically
synthesized TPTD is thus presented in the following case
study.
Case presentation
An 88-year-old female was referred to our hospital in
February 2011 after a fall from her bed 3 days earlier. Her past
medical history included colon cancer at the age of 67 years
and gastric cancer at the age of 85 years. She suffers from
rheumatoid arthritis (RA), with a drug history of 50 mg
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bucillamine and 5 mg prednisolone per day for more than
10 years. Two months prior to her fall, her prednisolone
dosage had been reduced to 2.5 mg per day. Clinical and
radiological examination revealed a Garden type II displaced
femoral neck fracture. The patient underwent surgery with a
Hansson hook-pin system within 3 h after her arrival (Fig. 1).
At 3 months post-operatively, CT imaging suggested the
presence of delayed union in the femoral neck, which was
treated with LIPUS (Fig. 2a). At 11 months, the patient still
complained of mild groin pain on ambulation. A diagnosis
of nonunion was given but LIPUS therapy was discontinued
because the patient rejected the therapy (Fig. 2b). Bone
mineral density (BMD) tests of the right hip revealed severe
osteoporosis measuring 38 % of the young adult mean, with
a BMD score of 0.303 g/cm2 and a T score of −4.4.
The patient accepted treatment with a once-weekly injection
of 56.5 μg chemically synthesized TPTD. At 18 months
post-operatively, CT imaging after 20 consecutive weekly
administrations of TPTD revealed signs of healing and the
patient reported a gradual decrease in groin pain on
ambulation (Fig. 2c). Complete union of the fracture was
obtained at 23 months (Fig. 2d). Serum examination after 36
weekly injections of TPTDwas as follows: C-reactive protein,
0.2 mg/dl; rheumatoid factor, 170 U/ml; alkaline phosphatase,
208 U/l; albumin, 4.0 g/dl; calcium, 8.8 mg/dl. The patient
reported no side effects during the entire period of TPTD
treatment.
Discussion
The risk of nonunion after internal fixation in elderly patients
with femoral neck fracture is approximately 20 to 35 %
[12]. In RA patients, up to 60 % of patients treated with
internal fixation of displaced femoral neck fractures require
revision surgery [13]. This is likely because of the reduced
mineralization rate in the bones of RA patients, which in turn
contributes to the poor mechanical stability and resultant
implant failure and nonunion of the femoral neck [13]. Aside
from RA itself, underlying anemia, poor nutrition, and
prolonged systemic corticosteroid use are also significant risk
factors that prevent fracture healing in the patient [14]. Taking
into account the increased incidence of delayed and nonunion
femoral neck fractures in RA patients, arthroplasty might have
been a better surgical choice for this patient. However,
because the patient was reluctant to undergo revision surgery
and she suffered from severe osteoporosis, a regime consisting
of a once-weekly dose of TPTD was chosen.
Fig. 1 Radiograph (a) and
CT imaging (b) show a Garden
type II displaced femoral
neck fracture at the time
of arrival, which was fixed
with a Hansson hook-pin
system (c)
Fig. 2 CT imaging at 3 months (a), 11 months (b), 18 months (c), and 23 months (d) CT imaging at 23 months shows that complete union was
obtained after 36 consecutive weekly administrations of teriparatide
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TPTD is the only anabolic drug currently available for
osteoporosis patients with an increased risk of fracture [5,
7]. TPTD has a strong anabolic activity on bone through the
activation of osteoblasts [3, 4]. The once-daily administration
of recombinant type TPTD has recently been reported to be
effective for treatment of nonunion fractures, including
humerus, odontoid, sternum, and femoral neck fractures
[8–11]. Of particular interest, patients in the report of
femoral neck fractures had no complications [11]. Thus,
this is the first report to show the efficacy of a once-
weekly administration of chemically synthesized TPTD
in a nonunion patient with RA and steroid use. Further
well-designed studies should be performed to confirm
the results of this case report.
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